Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. has entered into a Letter of Agreement with Sanmina Corporation to manufacture its LIBERTY® Endovascular Robotic System. Sanmina will serve as an additional manufacturing site, giving Microbot more capacity to meet expected demand from existing and new customer accounts.
The company states that expanding manufacturing with a global contract manufacturer is part of its cost reduction strategy. It expects the arrangement to improve operating efficiencies, lower costs, and support higher gross margins as LIBERTY adoption grows in the U.S. and internationally, including Israel and markets where it is pursuing CE Mark and other registrations.
Microbot Medical Inc. filed a current report noting that it has won the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY® Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The company reports continued adoption and increased use of LIBERTY following its Full Market Release in early April, including use at leading academic centers across several U.S. states. Management and SRT highlight the system’s innovative design, potential broad healthcare impact, and its aim to improve precision, efficiency, and safety in endovascular care.
Microbot Medical Inc. filed a current report describing new commercial progress for its LIBERTY® Endovascular Robotic System. A globally recognized academic center headquartered in Pennsylvania became the first health system in that state to adopt LIBERTY, joining existing customers in New York City and Boston.
The new customer operates multiple hospitals and multispecialty centers across Pennsylvania and New Jersey, and is the company’s second customer with facilities spanning two states. Microbot now has accounts in seven Eastern U.S. states and, following its recent full market release, plans to expand its sales footprint to the West Coast and further into international markets. A recent agreement expanding access to LIBERTY across certain U.S. federal healthcare systems, including veterans and military patient populations, is also highlighted.
Microbot Medical Inc. has entered into a vendor agreement with Lovell Government Services, creating an opportunity to sell its LIBERTY® Endovascular Robotic System at more than 2,000 U.S. government healthcare facilities, including those of the VA, Department of Defense and Indian Health Service.
Lovell, a Service-Disabled Veteran-Owned Small Business, will list the LIBERTY System on its Federal Supply Schedule contract, with activation expected during the third quarter of 2026, and make it available through platforms such as GSA Advantage, ECAT and DAPA. The relationship is intended to streamline procurement and support broader awareness and adoption across federal healthcare systems.
Microbot Medical Inc. announced that one of the largest healthcare systems in Michigan has become its first Midwest-based account to adopt the LIBERTY Endovascular Robotic System. This follows its first healthcare system customer in North Carolina, showing broader regional uptake across key U.S. markets.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, targeting a U.S. market of approximately 2.5 million procedures annually. The system also recently received regulatory approval in Israel, allowing marketing and sales there as the company advances its full market release strategy.
Microbot Medical Inc. reported a commercial update highlighting new adoption of its LIBERTY® Endovascular Robotic System. The company secured its first North Carolina-based healthcare system customer, described as a leading academic center with a multi-hospital network covering the state.
This new account expands LIBERTY’s geographic footprint from the southeast and mid-Atlantic into the broader northeast and South-Atlantic regions, aligning with Microbot’s commercial strategy following the system’s full market release. The report and accompanying press release also include standard cautionary language about forward-looking statements and refer readers to existing SEC filings for detailed risk factors.
Microbot Medical Inc. reported that Israel’s Ministry of Health AMAR Division has granted regulatory approval for its LIBERTY® Endovascular Robotic System. This approval allows the company to market and commercialize LIBERTY in Israel and obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions.
Israel is the second jurisdiction, and the first outside the U.S., to grant marketing clearance for LIBERTY. The company is also pursuing CE Mark certification and working toward completion by the end of 2026 to support a planned next phase of commercial expansion into the EU market, while the U.S. remains its primary focus.
Microbot Medical Inc. filed a current report describing plans for an analysts and investors conference call and webcast. The call will be held on Monday, May 18 at 3:00pm ET to review recent progress of the Full Market Release of its LIBERTY Endovascular Robotic System and to address company and product information it says was misrepresented in a recent unaffiliated third-party article. Management, along with two current LIBERTY users, Dr. Charles Briggs and Dr. Zachary Bercu, will discuss real-world experience with the system and respond to described inaccuracies. Access details are available via the company’s investor relations website and a teleconference registration link.
Microbot Medical Inc. reports its first revenue from the LIBERTY® Endovascular Robotic System during the fiscal quarter ended March 31, 2026, driven by a Limited Market Release. Early in the following quarter, the company began a Full Market Release.
By mid-second quarter 2026, revenue from LIBERTY had already exceeded total first quarter revenue, supported by more than doubling the number of accounts since the end of the limited release. Hospitals in six states, including Georgia, Florida, New York, Michigan, Massachusetts and North Carolina, are using the system, with Boston becoming the first city with multiple accounts.
The company highlights growing recurring orders, new accounts and a larger pipeline, as well as procedures that include what it believes is the world’s first robotic Prostatic Artery Embolization and other complex interventions. Updated occupational safety guidelines and visibility at major conferences are described as supportive of further U.S. and global commercial expansion.
Microbot Medical Inc. reported its first commercial revenue in the three months ended March 31, 2026 as it began selling the LIBERTY® Endovascular Robotic System. Revenue was $105,000, with cost of revenues of $103,000, resulting in a small gross profit while the business remains in its early launch phase.
The company recorded a net loss of $3.7 million, wider than the $2.6 million loss a year earlier, driven mainly by higher sales, general and administrative expenses as commercialization ramps, partly offset by increased financing income. Cash and cash equivalents were $3.7 million and marketable securities were $68.8 million, supporting total assets of $78.1 million and shareholders’ equity of $74.1 million.
Management notes that available cash and marketable securities are sufficient to fund operations for more than twelve months, even as the company expects continued operating losses while it scales manufacturing, sales, and ongoing development of LIBERTY® and related technologies.